



Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 7-80) PATENT AND TRADEMARK OFFICE  LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)	ATTORNEY DOCKET NO.: 14014.0312	SERIAL NO. 09/196,867
	APPLICANT: Kelsall et al	
	FILING DATE: November 20, 1998	GROUP: 1644

#### U.S. PATENT DOCUMENTS

EXAMINER INITIALS	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

#### FOREIGN PATENT DOCUMENTS


#### OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

As	C1	Gordon et al., "Both anti-CD11a (LFA-1) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis," <i>J Neuroimmunology</i> 62: 153-160, 1995
	C2	Rosen, Hugh "Role of CR3 in Induced Myelomonocytic Recruitment: Insights From In Vivo Monoclonal Antibody Studies in the Mouse," <i>J Leuk. Biol.</i> 48: 465-469, 1990
	C3	Rosen et al., "Antibody To the Murine Type 3 Complement Receptor Inhibits T Lymphocyte-Dependent Recruitment of Myelomonocytic Cells In Vivo," <i>J Exp. Med.</i> 169: 535-548, 1989
	C4	Rosen and Gordon "Monoclonal Antibody To The Murine Type 3 Complement Receptor Inhibits Adhesion of Myelomonocytic Cells in Vitro and Inflammatory Cell Recruitment In Vivo," <i>J. Exp. Med.</i> 166: 1685-1701, 1987

EXAMINER: <i>Amy DeGennaro</i>	DATE CONSIDERED: 9-26-02	TECH CENTER 1600/2900
--------------------------------	--------------------------	-----------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED  
JUL 10 2002  
TECH CENTER 1600/2900